

Open
Review

Metrnl: a secreted protein with new emerging functions

Si-li ZHENG^{1, #}, Zhi-yong LI^{1, #}, Jie SONG¹, Jian-min LIU², Chao-yu MIAO^{1, 3, *}

¹Department of Pharmacology, Second Military Medical University, Shanghai 200433, China; ²Stroke Center & Department of Neurosurgery, Changhai Hospital, Second Military Medical University, Shanghai 200433, China; ³Center of Stroke, Beijing Institute for Brain Disorders, Beijing 100069, China

Secreted proteins play critical roles in physiological and pathological processes and can be used as biomarkers and therapies for aging and disease. Metrnl is a novel secreted protein homologous to the neurotrophin Metrnl. But this protein, unlike Metrnl that is mainly expressed in the brain, shows a relatively wider distribution in the body with high levels of expression in white adipose tissue and barrier tissues. This protein plays important roles in neural development, white adipose browning and insulin sensitization. Based on its expression and distinct functions, this protein is also called Cometin, Subfatin and Interleukin 39, which refer to its neurotrophic effect, adipokine function and the possible action as a cytokine, respectively. The spectrum of Metrnl functions remains to be determined, and the mechanisms of Metrnl action need to be elucidated. In this review, we focus on the discovery, structural characteristics, expression pattern and physiological functions of Metrnl, which will assist in developing this protein as a new therapeutic target or agent.

Keywords: secreted proteins; Metrnl; Cometin; Subfatin; adipokine; neurotrophin; insulin sensitization; white adipose browning

Acta Pharmacologica Sinica (2016) 37: 571–579; doi: 10.1038/aps.2016.9; published online 11 Apr 2016

Introduction

Secreted proteins play critical roles in physiological and pathological processes and can be used as biomarkers and therapies for aging and disease^[1-7]. Because adipose tissue is the largest endocrine organ, we have focused on adipose-derived secreted proteins (also known as adipokines) and explored their functions over the past decade^[8-16]. In addition to clarifying the roles and molecular mechanisms as well as possible clinical applications of known adipokines (such as NAMPT/Visfatin)^[15-28], we have made efforts to discover new adipokines. Most recently, we identified a novel adipokine, Metrnl, also known as Meteorin(Metrnl)-like, Cometin and Subfatin, and revealed its insulin sensitizing action, which may translate it into a promising therapeutic target for insulin resistance^[29, 30].

Metrnl is a protein homologous to the neurotrophic factor Metrnl. Although the expression and functions of Metrnl have been explored extensively, studies on Metrnl are quite limited. In this review, we summarize the discovery, structural char-

acteristics, expression pattern, functions and mechanisms of action of Metrnl that have been reported to date.

Discovery of Metrnl

The human genome contains approximately 20687 protein-coding genes^[31], but most of their expression patterns and functions remain unknown. To discover novel functional proteins, advanced bioinformatic techniques show great potential. Using these techniques, a number of research groups noticed the Metrnl gene before the subsequent identification of the protein^[29, 32-34].

The Metrnl gene is located on mouse chromosome 11qE2 and human chromosome 17q25.3^[29, 35]. Its specific location on the q-arm terminal end of human chromosome 17 has recently attracted attention because a cyto-molecular analysis of a case of ring 17 syndrome showed that the breakpoints are very close to the telomeric ends, thus making Metrnl a candidate gene that is potentially involved in some of the phenotypic features related to the ring chromosome 17^[33].

The protein homologous to Metrnl, Metrnl, was reported by Nishino *et al* in 2004^[36]. Considering the obvious role of Metrnl in the central nervous system and following the demonstration of the Metrnl gene being a new, direct target of PAX2/5/8

These authors contributed equally to this work.

* To whom correspondence should be addressed.

E-mail cymiao@smmu.edu.cn

Received 2015-12-21 Accepted 2016-01-24

for otic development^[32], Jorgensen *et al* first described Metrnl protein and demonstrated its function as a neurotrophic factor similar to Metrnl in 2012^[35]. Our lab screened for new adipokines in a global gene expression profiling of different adipose depots with bioinformatic methods in 2007 and early 2008. We identified Metrnl as a novel adipokine^[29]. Although Jorgensen *et al* and we discovered Metrnl protein in entirely independent ways, both labs verified Metrnl as a secreted protein^[29, 35].

Metrnl as a novel secreted protein homologous to Metrnl

Bioinformatic analysis predicts that the Metrnl proteins encoded in the mouse, rat, and human genomes contain 311 amino acids, with a NH₂-terminal signal peptide of 45 amino acids and without any transmembrane region, suggesting a mature protein that contains 266 amino acids (~30 kDa) when secreted. The secretion of Metrnl has been verified by both Jorgensen *et al* and us, independently. In brief, a C-terminally His-tagged version of mouse Metrnl was cloned into a eukaryotic expression vector, which was transfected into HEK293, COS-7^[29] or HEK293F^[35] cells. Metrnl was detected in both cell lysate and serum-free medium of transfected cells by western blotting with a Metrnl antibody^[29, 35].

It is predicted that 239 amino acids (77%) are identical in the mouse and human Metrnl proteins (Figure 1). Moreover, orthologues for Metrnl are found in all vertebrates, including zebrafish and the frog *Xenopus tropicalis* (Figure 1), but not in invertebrates such as the fruit fly (*Drosophila melanogaster*) and the nematode (*Caenorhabditis elegans*)^[29, 35, 37].

Metrnl shows approximately 40% amino acid identity with

Metrnl, with all ten cysteine residues in the mature sequence conserved. Structurally unrelated to other known proteins, Metrnl and Metrnl constitute a new evolutionarily conserved two-member protein family^[29, 35, 37] (Figure 2).

The gene product encoded by Metrnl was first described by Nishino and co-workers in 2004 and was shown to play an important role in the regulation of glial cell differentiation and in the induction of axonal extension. Thus, the initial name of this protein, Meteorin, was a vivid description of its function in transforming glial cells into cells with an elongated tail that look like meteors^[36]. As the homologous protein, Metrnl protein was accordingly annotated as Meteorin-like in public databases at that time because neither its expression nor its functions had been reported^[29, 35].

Unlike Metrnl, the prediction of N-glycosylation sites in Metrnl indicates a single potential N-glycosylation site at amino acid 103 in mouse Metrnl. This was proven by both Jorgensen *et al* and us using recombinant mouse Metrnl-his₆ protein. In both laboratories, the recombinant protein was purified by affinity chromatography and then separated by SDS-PAGE. Metrnl purified by this method appeared much heavier than the calculated molecular weight of Metrnl-his₆, lacking the signal peptide^[29, 35]. In our case, we observed two bands between 34 and 43 kDa, which were recognized by anti-Metrnl and anti-His₆ antibodies in SDS-PAGE analysis, and we identified both these bands as Metrnl by mass spectrometry^[29]. In contrast, Jorgensen *et al* observed one band of approximately 34 kDa by SDS-PAGE analysis, which, when analyzed by MALDI-TOF MS, had a mass of 33.8 kDa with a shoulder at 33.4 kDa^[35]. Because the bioinformatic prediction suggests




Figure 1. Amino acid sequences of Metrnl precursors in several vertebrates. Identical amino acids are marked in black, and similarity is marked in gray. The putative NH₂-terminal signal sequences are indicated by the red frame, and the potential glycosylation site is indicated by a red star.



Figure 2. Amino acid sequences of human Metrn1 and Metrn. Identical amino acids are marked in black, and similarity is marked in gray. The putative NH₂-terminal signal sequences are indicated by the red frame.

that the mouse Metrn1 contains one potential N-glycosylation site, the two labs then incubated the purified recombinant protein with glycopeptidase F^[29] or N-glycanase^[35], both obtaining a single band with a decreased molecular weight closer to the calculated size. These experimental results from both groups indicate that the larger molecular weight proteins represent glycosylated forms of Metrn1, thus proving that Metrn1 is indeed post-translationally glycosylated, which may facilitate its secretion from the cells^[38].

However, the N-glycosylation site in mouse Metrn1 is not conserved in Metrn or human Metrn1 (Figure 1), suggesting that the glycosylation of mouse Metrn1 may not play a central role in its function.

Metrn1 expression in various tissues

Homologous to Metrn1, Metrn was discovered earlier and is mainly expressed in the nervous system both during development and in adult mice^[37]. It has been reported that during embryonic mouse development, Metrn is widely expressed in undifferentiated neural progenitors and in the astrocyte lineage, including radial glia^[36]. In the adult mouse brain, Metrn is highly expressed in Bergmann glia and in a few discrete neuronal populations, with low levels of Metrn in astrocytes distributed ubiquitously throughout the brain^[37,39,40].

In view of Metrn expression being closely associated with the brain, there is now great interest in the Metrn1 expression pattern, especially concerning whether this novel protein is also expressed mainly in brain and whether it plays a similar role as a neurotrophic factor in neurogenesis like Metrn.

However, the structural similarity of Metrn1 and Metrn do not seem to grant a similar expression pattern. Recent studies of Metrn1 have demonstrated that it is widely expressed in adult mouse tissues at differing expression levels, but its highest expression is obviously not in the brain^[29].

In the nervous system

Assessed by *in situ* hybridization (ISH), Metrn1 expression is found in very restricted sites within the brain during development. Metrn1 mRNA expression appears weak in the otic vesicle of medaka embryos^[32], but during early mouse devel-

opment, this transcript is found exclusively in the floor plate, and from E13.5, it is also found in dorsal root ganglions (DRG) and the inner ear but apparently not in the adult nervous system^[35].

Nevertheless, Metrn1 is reported to be expressed in adult mouse brain, with a much lower expression level than that found in other tissues, such as white adipose tissue and skin^[29,41].

In adipose tissue

Examined by real-time PCR, the highest expression level of Metrn1 is in subcutaneous white adipose tissue of both rodents and humans, with expression also detected in various tissues, including liver, spleen, muscle, heart, thymus, forebrain, midbrain, hindbrain, omental adipose tissue, subcutaneous adipose tissue, perivascular adipose tissue and interscapular adipose tissue^[29].

Metrn1 protein is easily detected in the incubation medium of white adipose tissue by Western blot and ELISA^[29,30], which is consistent with its secretion. To further clarify the cell types in which Metrn1 is mainly expressed, Metrn1 expression was first compared between adipocytes and stromal cells separated by collagenase digestion of fat tissue, with no significant difference observed^[29]. Upon comparing Metrn1 expression between RAW264.7 macrophages and 3T3-L1 adipocytes, much lower expression was found in the macrophages^[29]. These results indicate that both adipocytes and stromal cells but not unactivated macrophages are the main cell types expressing Metrn1. Immunohistochemical analysis of the fat tissue shows that Metrn1 is distributed throughout the adipose tissue, except in the lipid droplets^[29].

In mucosal tissues, skin and activated macrophages

According to Metrn1 expression data from the human BIGE database, the highest expression of Metrn1 is in activated monocytes, followed by digestive and respiratory mucosal tissues and the skin^[41]. Our unpublished results on the real-time PCR detection of Metrn1 expression in various tissues also showed that Metrn1 is highly expressed in digestive tract and lung (data not shown).

With strong expression in activated human monocytes

according to the BIGE database, *Metnrl* was further found to be produced by alternatively activated macrophages and macrophage colony stimulating factors (M-CSF)-stimulated bone marrow macrophages^[41].

In addition, under resting conditions, *Metnrl* is expressed in fibroblasts but not in keratinocytes or peripheral blood mononuclear cells, whereas its expression is increased in IFN γ -treated keratinocytes^[41]. Moreover, significant up-regulation of *Metnrl* expression was observed in familial primary localized cutaneous amyloidosis (FPLCA)^[42], psoriasis, prurigo nodularis, actinic keratosis and atopic dermatitis and in synovial membranes of human rheumatoid arthritis, thus suggesting a potential role of *Metnrl* in both innate and acquired immune responses^[41].

Function of *Metnrl*

Metnrl acts as a neurotrophic factor

Many secreted proteins, including NGF, GDNF and *Metnrl*, are neurotrophic factors that nourish neurons and play central roles in neuronal development, maintenance and regeneration^[36, 37, 43–47]. Recently, Jorgensen *et al*^[35] reported the neurotrophic activity of *Metnrl* in neurite outgrowth and neuroblast migration *in vitro* and in the survival of spiral ganglion neurons *in vivo*.

Using *Metnrl* as a positive control, both proteins were tested on cultures of dissociated dorsal root ganglia. In the *Metnrl* treated group, neurite outgrowth was dose dependent and not significantly different from that induced by *Metnrl*. Moreover, simultaneous treatment with *Metnrl* and *Metnrl* showed an additive effect, with significantly more neurites compared to treatment with either factor alone^[35]. Either the Jak inhibitor I (JAKi) or the MEK inhibitor U0126 abrogates the *Metnrl* induced neurite outgrowth, indicating that both the Jak-STAT3 and MEK-ERK pathways are involved in the effect of *Metnrl*^[35]. In rat subventricular zone explants, *Metnrl* induced a significant increase of neuroblast migration, with a similar effect to that induced by the positive control, stromal cell-derived factor 1 α ^[35]. In a further investigation of the possible role of *Metnrl* in the adult inner ear, Jorgensen *et al* used a guinea pig model whose auditory sensory cells had been destroyed. The hearing-impaired animals treated with recombinant *Metnrl* exhibited a significant therapeutic effect in retaining electrical responsiveness of the auditory neurons, which was further supported by a stereological analysis indicating more spiral ganglion neurons in the treated animals than in the control group^[35].

Later, Watanabe *et al*^[48] reported that *Metnrl* is a latent process (LP) gene. The expression of these genes is upregulated during the latent process, a preparation step for cellular function, and this expression is required for subsequent neurite extension. Small interfering RNA targeting of *Metnrl* significantly inhibits NGF-induced neurite extension of PC12 cells, an adrenal chromaffin cell line that is a well-characterized model of nerve cells. This inhibition is partially prevented by *Metnrl* rescue constructs, which indicates an indispensable role of *Metnrl* in neurite extension. The effect of small

interfering RNA knockdown of *Metnrl* expression on neurite extension is also observed in primary dissociated hippocampal neurons of rats, indicating that the role of *Metnrl* in neurite extension in primary neurons is consistent with that in the PC12 cell line^[48]. Given that persistent activation of ERK is required for the NGF-induced differentiation of PC12 cells, *Metnrl* expression was shown to be dependent on ERK activity^[48]. Further, the neurotrophic factors, *ie*, pituitary adenylate cyclase-activating peptide (PACAP) and forskolin, induce weaker ERK phosphorylation but greater *Metnrl* expression than NGF does, suggesting that *Metnrl* expression is regulated not only by ERK but also by other signaling pathways, at least in response to PACAP and forskolin^[48].

Metnrl induces white adipose browning

In mammals, there are two main types of adipose tissue: white adipose tissue (WAT), which stores energy, and brown adipose tissue (BAT), which dissipates energy^[49–51]. WAT and BAT differ at the functional, morphological, and molecular levels^[51–53]. However, upon thermogenic stimuli, WAT possesses the capacity to generate brown-like adipocytes (also called beige adipocytes), and this process is termed “browning” or “beiging”^[53, 54]. Due to its great therapeutic potential in developing new therapies for metabolic diseases, the browning of WAT has received much attention.

Recently, Rao *et al*^[55] showed a role for *Metnrl* in the browning of white adipose tissue. *Metnrl*, which Rao *et al* identified as a PGC-1 α -dependent myokine in skeletal muscle, can be induced in muscle after exercise, a physiological stimulus that also increases PGC-1 α expression^[55]. The authors demonstrated that muscle-specific expression of PGC-1 α promotes browning of the subcutaneous and epididymal white adipose tissue^[55], a process that correlates with the ability to defend body temperature in cold environments^[53, 56–58]. These results suggest that *Metnrl* mediates muscle-fat crosstalk to promote the expression of genes that are associated with browning of the white adipose tissue^[55].

Rao *et al* also showed that increasing circulating *Metnrl* in mice, either by delivering a *Metnrl*-expressing adenoviral vectors to the liver or through the administration of recombinant *Metnrl*, produces remarkable increases in the expression of genes associated with beige fat thermogenesis and anti-inflammatory cytokines in white adipose tissue^[55]. *Metnrl* was also shown to induce a thermogenic phenotype when expressed locally in adipose tissue *in vivo*. However, it should be noted that this phenotype can only be maintained for a short period (fewer than 10 days).

Examination of mRNA profiles from the subcutaneous white fat of mice with increased circulating *Metnrl* shows significant increases in several genes associated with alternative macrophage activation. *Metnrl* expression also increases the production of IL-4 and IL-13 as well as catecholamines in the adipose tissue. This suggests that *Metnrl* induces a phenotypic switch in adipose tissue macrophages *in vivo*, along with production of pro-thermogenic catecholamines, possibly via the induction of the M2-regulatory cytokines IL-4

and IL-13^[55]. The browning response induced by Metrnl is IL-4/13 dependent because disruption of IL-4/13 signaling in STAT6 knockout mice causes no change in alternative macrophage activation but attenuates the effects of IL-4/13 on the regulation of thermogenic or β -oxidation genes and reduces the content of catecholamines^[55]. The primary source of IL-4/13 upon Metrnl treatment is shown to be eosinophils, the number of which increases in the adipose tissue when circulating Metrnl is elevated^[55].

Finally, blocking Metrnl actions *in vivo* by anti-Metrnl antibody results in reduced mRNA expression of IL-4/13 along with a reduced number of eosinophils induced upon acute cold exposure for 24 h. The anti-Metrnl antibody also significantly inhibits the expression of genes that are characteristic of M2 macrophages and adipose thermogenesis induced by 72 h of cold exposure, thereby implicating the role of Metrnl in cold adaptation^[55].

Metrnl antagonizes insulin resistance

In addition to being the largest reservoir for energy storage, adipose tissue is a highly active endocrine organ that synthesizes and secretes proteins/peptides termed adipokines^[10, 59]. Adipokines participate in the regulation of multiple physiological functions, including metabolism, insulin sensitivity, cardiocerebrovascular function, immunity and inflammation^[10, 60]. Dysregulated production or secretion of adipokines is associated with the pathogenesis of obesity-linked disorders^[61, 62]. With potential clinical relevance, adipokines are promising candidates as new therapeutic compounds or targets in the treatment of obesity and its related diseases^[2, 61].

Our lab has identified Metrnl as an adipokine that is abundantly expressed in rat, mouse and human subcutaneous white adipose tissue, with relatively lower expression levels found in brown adipose tissue and a much lower expression level in the brain^[29]. In addition, Metrnl is downregulated in white adipose tissue of caloric restriction rats but is dramatically upregulated during white adipocyte differentiation and in the white adipose tissue of diet-induced obese mice^[29]. These results suggested a role for Metrnl in white adipose biology and metabolic homeostasis, leading us to explore the function of Metrnl in white adipose tissue.

Adipogenesis, the differentiation of fibroblast-like mesenchymal stem cells into adipocytes, plays a central role in the regulation of whole body energy metabolism^[63]. Metrnl is detectable both in the incubation medium of white adipose tissue and in the culture medium of either primary adipocytes or 3T3-L1 adipocytes^[29, 30]. To study the adipogenic potential of Metrnl, we employed gain-of-function and loss-of-function experiments using 3T3-L1 adipocytes as an *in vitro* model of adipogenesis to demonstrate that Metrnl promotes lipid accumulation and upregulates markers specific to mature adipocytes^[30]. Importantly, the expression of PPAR γ , which is the key regulator of adipocyte differentiation^[64-66], is induced by Metrnl protein in a concentration-dependent manner, indicating that secreted Metrnl promotes adipocyte differentiation^[30].

We further demonstrate an insulin sensitizing role of Metrnl

using genetically engineered mouse models. Tested by various methods, insulin resistance induced by a high-fat diet (HFD) is exacerbated in adipocyte-specific Metrnl knockout mice, whereas transgenic mice overexpressing Metrnl specifically in adipocytes were protected from diet-induced insulin resistance. Moreover, the overexpression of Metrnl in adipose tissue also antagonizes insulin resistance in mice with leptin deficiency^[30].

We provide evidence that adipose Metrnl is most likely to ameliorate overall insulin resistance through its action on local adipose tissue in an autocrine or paracrine fashion^[30]. First, though the phenotypes with regards to insulin resistance in these mouse models are obvious and unambiguous, their serum Metrnl concentrations remain unchanged compared to the corresponding control mice. Second, the insulin-stimulated phosphorylation of AKT is enhanced by adipocyte Metrnl in white adipose tissue, but not in other major metabolic tissues (brown adipose tissue, muscle and liver). Third, increasing the circulating Metrnl levels via the intravenous administration of recombinant Metrnl for 1 week is unable to rescue insulin resistance in adipose-specific Metrnl knockout mice fed a HFD. Moreover, acute intravenous injection with recombinant Metrnl has no hypoglycemic action in HFD-fed C57 obese mice or in leptin knockout obese mice^[30].

Both *in vitro* and *in vivo*, Metrnl promotes adipocyte differentiation, which is a key factor in forming functional fat for insulin sensitivity and lipid metabolism. We have detected gene markers related to adipocyte differentiation and lipid metabolism in white adipose tissue of both HFD-fed Metrnl knockout mice and Metrnl transgenic overexpression mice and found that Metrnl upregulates key transcription factors for adipocyte differentiation (PPAR γ , C/EBP α) and lipid metabolism genes for lipid transport (FABP4, CD36), lipogenesis (ACC, FASN), lipolysis (Lipe, PNPLA), and lipid storage (Perilipin). In addition, the overexpression of Metrnl decreased the proportion of small adipose cells^[30], which is consistent with insulin sensitization^[67-69].

The transcription factor PPAR γ is the key regulator of the fully differentiated and insulin-sensitive adipose cell phenotype, with consequences for the proper functioning of the adipose tissue and whole-body insulin sensitivity^[64-66]. The expression of PPAR γ is increased markedly in adipose tissue of Metrnl transgenic mice, in agreement with the *in vitro* results. We subsequently demonstrated that PPAR γ plays a critical role in Metrnl-mediated beneficial effects by using long-term treatment with two different small-molecule inhibitors of PPAR γ as well as the knockdown of PPAR γ . The inhibition or knockdown of PPAR γ completely abolished the insulin-sensitizing effect of Metrnl in HFD-fed Metrnl transgenic mice, indicating that Metrnl-mediated insulin sensitization occurs through the PPAR γ pathway^[30].

We also investigated many other factors that are possibly related to the insulin sensitization of Metrnl^[30]. For example, adipocyte Metrnl prevents an increase in TNF- α by chronic HFD but not acute LPS, indicating a role of Metrnl in the inhibition of HFD-induced adipose inflammation. Adipocyte

Metnrl attenuates HFD-induced hypertriglyceridemia but not HFD-induced hypercholesterolemia or the accumulation of liver triglyceride. Metnrl enhances serum triglyceride clearance during acute lipid overload test and elevates the expression and activity of lipase in adipose tissue. These results all indicate a role of Metnrl in the activation of adipose lipid metabolism. However, no changes have been observed in body weight, food intake, lean/fat mass, distribution of adipose tissue, or energy expenditure in either Metnrl adipose-specific knockout or transgenic overexpression mice compared to control mice^[30]. In particular, considering a physiological role for Metnrl in cold adaption as a hormone that regulates immune-adipose interactions to increase beige fat thermogenesis, as reported by Rao *et al*^[55], we explored whether this mechanism is involved in our transgenic mouse models. We did not observe any significant changes in IL-4/13 expression, M2 macrophage activation, eosinophil accumulation, or thermogenic gene expression in the white adipose tissue of these transgenic mouse models, indicating that no browning of white adipose tissue occurs^[30]. This discrepancy between these studies may be caused by the different animal models and intervention methods, for instance, the relatively acute models used by Rao *et al* versus the chronic models used in

our study.

We have also noted a meeting abstract reporting that Metnrl is mainly expressed in undifferentiated osteoblasts and hypertrophic chondrocytes and reduces the terminal differentiation of human osteoblastic MG63, which may be associated with the inhibition of Metnrl on transcription activity of AP-1^[70].

Concluding remarks

Metnrl is a novel secretory protein with three new emerging functions (Figure 3). First, Metnrl acts as a neurotrophic factor that promotes neurite outgrowth and neuroblast migration *in vitro* and supports the survival of spiral ganglion neurons *in vivo*. Second, Metnrl is involved in cold adaption by regulating immune-adipose interactions to increase beige fat thermogenesis. Third, Metnrl plays an important role in the biology of white adipose tissue, improving adipose function and antagonizing obesity-induced insulin resistance. With its neurotrophic activity and beneficial metabolic effect, this protein could be expected to provide novel therapeutic strategies for certain diseases. However, the utilization of this newly described protein as a therapeutic target or agent requires much work to be done to understand its functional spectrum in health and disease, especially the key mechanisms that




Figure 3. Known functions of Metnrl in white adipose tissue and neurocytes. (A) Overexpression of Metnrl upregulates PPAR γ in adipocytes via an autocrine/paracrine mechanism, which inhibits adipose inflammation, enhances adipocyte differentiation, activates lipid metabolism, and ultimately reduces insulin resistance. (B) Administration of abundant Metnrl causes trafficking of eosinophils into white adipose tissue and increases local IL-4/13, which promotes alternative macrophage activation along with increased norepinephrine. Through this mechanism, Metnrl transiently induces white adipose browning for less than ten days. (C) Nerve growth factor (NGF), pituitary adenylate cyclase-activating peptide (PACAP) and forskolin induce Metnrl expression in PC12 cells. Metnrl protein promotes neurite outgrowth and neuroblast migration via the Jak-STAT3 and MEK-ERK pathways and plays a neuroprotective role *in vivo*.

initiate its actions. Important questions exist, such as what is the role of *Metnrl* in barrier tissues; how does *Metnrl* influence nerve system function; and what, if any, specific receptor exists for *Metnrl*?

Because research into this novel bioactive protein, *Metnrl*, has only just begun, its function and mechanisms of action remain largely unknown. As many as five names (*Metnrl*, Meteorin-like, Cometin, Subfatin, IL-39) have been proposed for this novel protein. Meteorin-like, simply highlighting *Metnrl*'s homology with Meteorin (*Metrn*), was the initial name of the protein annotated in public databases at the time when neither its expression nor its functions had been reported. The most recent studies on *Metnrl* have revealed that the expression patterns and functions of *Metnrl* appear to be quite different from those of Meteorin (*Metrn*). Thus, the name "Meteorin-like" is not appropriate, which has led to new names being proposed, including Cometin, Subfatin and IL-39, based on the expression features and functions of this protein. However, one name for each function of the same protein is inappropriate, makes further work complicated for researchers, authors and readers, and is unfavorable for broad studies of this novel protein. To solve this issue, we suggest *Metnrl*, identical to the gene symbol, as the protein designation in the future literature. With the gene symbols being unique, *Metnrl* could uniquely represent the encoded protein, thus allowing for clear and unambiguous reference to *Metnrl* protein in scientific communications.

Acknowledgements

This work was supported by grants from the National Natural Science Foundation of China (No 81130061, 81202572, and 81373414).

References

- 1 Kaiser J. Aging. 'Rejuvenation factor' in blood turns back the clock in old mice. *Science* 2014; 344: 570–1.
- 2 Fasshauer M, Bluher M. Adipokines in health and disease. *Trends Pharmacol Sci* 2015; 36: 461–70.
- 3 Zhang ZY, Dodd GT, Tiganis T. Protein tyrosine phosphatases in hypothalamic insulin and leptin signaling. *Trends Pharmacol Sci* 2015; 36: 661–74.
- 4 Wang LL, Miller D, Wanders D, Nanayakkara G, Amin R, Judd R, *et al*. Adiponectin downregulation is associated with volume overload-induced myocyte dysfunction in rats. *Acta Pharmacol Sin* 2016; 37: 187–95.
- 5 Siqueiros-Cendon T, Arevalo-Gallegos S, Iglesias-Figueroa BF, Garcia-Montoya IA, Salazar-Martinez J, Rascon-Cruz Q. Immunomodulatory effects of lactoferrin. *Acta Pharmacol Sin* 2014; 35: 557–66.
- 6 Zhu Y, Chen YL, Li C, Ding XY, Xu GY, Hu LL, *et al*. The effect of inhibition of endoplasmic reticulum stress on lipolysis in white adipose tissue in a rat model of chronic kidney disease. *Acta Pharmacol Sin* 2014; 35: 356–62.
- 7 Zhang YM, Li MX, Tang Z, Wang CH. Wogonin suppresses osteopontin expression in adipocytes by activating PPAR α . *Acta Pharmacol Sin* 2015; 36: 987–97.
- 8 Wang P, Xu TY, Guan YF, Su DF, Fan GR, Miao CY. Perivascular adipose tissue-derived visfatin is a vascular smooth muscle cell growth factor: role of nicotinamide mononucleotide. *Cardiovasc Res* 2009; 81: 370–80.
- 9 Wang P, Yang FJ, Du H, Guan YF, Xu TY, Xu XW, *et al*. Involvement of leptin receptor long isoform (LepRb)-STAT3 signaling pathway in brain fat mass- and obesity-associated (FTO) downregulation during energy restriction. *Mol Med* 2011; 17: 523–32.
- 10 Miao CY. Introduction: adipokines and cardiovascular disease. *Clin Exp Pharmacol Physiol* 2011; 38: 860–3.
- 11 Li ZY, Wang P, Miao CY. Adipokines in inflammation, insulin resistance and cardiovascular disease. *Clin Exp Pharmacol Physiol* 2011; 38: 888–96.
- 12 Wang P, Vanhoutte PM, Miao CY. Visfatin and cardio-cerebro-vascular disease. *J Cardiovasc Pharmacol* 2012; 59: 1–9.
- 13 Miao CY, Li ZY. The role of perivascular adipose tissue in vascular smooth muscle cell growth. *Br J Pharmacol* 2012; 165: 643–58.
- 14 Song DD, Chen Y, Li ZY, Guan YF, Zou DJ, Miao CY. Protein tyrosine phosphatase 1B inhibits adipocyte differentiation and mediates TNF α action in obesity. *Biochim Biophys Acta* 2013; 1831: 1368–76.
- 15 Wang P, Miao CY. NAMPT as a Therapeutic Target against Stroke. *Trends Pharmacol Sci* 2015; 36: 891–905.
- 16 Wang P, Li WL, Liu JM, Miao CY. NAMPT and NAMPT-controlled NAD metabolism in vascular repair. *J Cardiovasc Pharmacol* 2015 Oct 17. [Epub ahead of print]
- 17 Zhang RY, Qin Y, Lv XQ, Wang P, Xu TY, Zhang L, *et al*. A fluorometric assay for high-throughput screening targeting nicotinamide phosphoribosyltransferase. *Anal Biochem* 2011; 412: 18–25.
- 18 Wang P, Xu TY, Guan YF, Tian WW, Viollet B, Rui YC, *et al*. Nicotinamide phosphoribosyltransferase protects against ischemic stroke through SIRT1-dependent adenosine monophosphate-activated kinase pathway. *Ann Neurol* 2011; 69: 360–74.
- 19 Wang P, Guan YF, Du H, Zhai QW, Su DF, Miao CY. Induction of autophagy contributes to the neuroprotection of nicotinamide phosphoribosyltransferase in cerebral ischemia. *Autophagy* 2012; 8: 77–87.
- 20 Wang P, Zhang RY, Song J, Guan YF, Xu TY, Du H, *et al*. Loss of AMP-activated protein kinase- α 2 impairs the insulin-sensitizing effect of calorie restriction in skeletal muscle. *Diabetes* 2012; 61: 1051–61.
- 21 Song J, Ke SF, Zhou CC, Zhang SL, Guan YF, Xu TY, *et al*. Nicotinamide phosphoribosyltransferase is required for the calorie restriction-mediated improvements in oxidative stress, mitochondrial biogenesis, and metabolic adaptation. *J Gerontol A Biol Sci Med Sci* 2014; 69: 44–57.
- 22 Zhao Y, Liu XZ, Tian WW, Guan YF, Wang P, Miao CY. Extracellular visfatin has nicotinamide phosphoribosyltransferase enzymatic activity and is neuroprotective against ischemic injury. *CNS Neurosci Ther* 2014; 20: 539–47.
- 23 Wang P, Xu TY, Wei K, Guan YF, Wang X, Xu H, *et al*. ARRB1/ β -arrestin-1 mediates neuroprotection through coordination of BECN1-dependent autophagy in cerebral ischemia. *Autophagy* 2014; 10: 1535–48.
- 24 Wang P, Du H, Zhou CC, Song J, Liu X, Cao X, *et al*. Intracellular NAMPT-NAD $^{+}$ -SIRT1 cascade improves post-ischaemic vascular repair by modulating Notch signalling in endothelial progenitors. *Cardiovasc Res* 2014; 104: 477–88.
- 25 Wang P, Guan YF, Li WL, Lu GC, Liu JM, Miao CY. Nicotinamide phosphoribosyltransferase facilitates post-stroke angiogenesis. *CNS Neurosci Ther* 2015; 21: 475–7.
- 26 Xu TY, Zhang SL, Dong GQ, Liu XZ, Wang X, Lv XQ, *et al*. Discovery

- and characterization of novel small-molecule inhibitors targeting nicotinamide phosphoribosyltransferase. *Sci Rep* 2015; 5: 10043.
- 27 Wang X, Xu TY, Liu XZ, Zhang SL, Wang P, Li ZY, et al. Discovery of Novel Inhibitors and Fluorescent Probe Targeting NAMPT. *Sci Rep* 2015; 5: 12657.
- 28 Zhao Y, Guan YF, Zhou XM, Li GQ, Li ZY, Zhou CC, et al. Regenerative neurogenesis after ischemic stroke promoted by nicotinamide phosphoribosyltransferase-nicotinamide adenine dinucleotide cascade. *Stroke* 2015; 46: 1966–74.
- 29 Li ZY, Zheng SL, Wang P, Xu TY, Guan YF, Zhang YJ, et al. Subfatin is a novel adipokine and unlike Meteorin in adipose and brain expression. *CNS Neurosci Ther* 2014; 20: 344–54.
- 30 Li ZY, Song J, Zheng SL, Fan MB, Guan YF, Qu Y, et al. Adipocyte Metrnl antagonizes insulin resistance through PPAR γ signaling. *Diabetes* 2015; 64: 4011–22.
- 31 Kim MS, Pinto SM, Getnet D, Nirujogi RS, Manda SS, Chaerkady R, et al. A draft map of the human proteome. *Nature* 2014; 509: 575–81.
- 32 Ramialison M, Bajoghli B, Aghaallaei N, Ettwiller L, Gaudan S, Wittbrodt B, et al. Rapid identification of PAX2/5/8 direct downstream targets in the otic vesicle by combinatorial use of bioinformatics tools. *Genome Biol* 2008; 9: R145.
- 33 Surace C, Piazzolla S, Sirelto P, Digilio MC, Roberti MC, Lombardo A, et al. Mild ring 17 syndrome shares common phenotypic features irrespective of the chromosomal breakpoints location. *Clin Genet* 2009; 76: 256–62.
- 34 Chung J, Kubota H, Ozaki Y, Uda S, Kuroda S. Timing-dependent actions of NGF required for cell differentiation. *PLoS One* 2010; 5: e9011.
- 35 Jorgensen JR, Fransson A, Fjord-Larsen L, Thompson LH, Houchins JP, Andrade N, et al. Cometin is a novel neurotrophic factor that promotes neurite outgrowth and neuroblast migration *in vitro* and supports survival of spiral ganglion neurons *in vivo*. *Exp Neurol* 2012; 233: 172–81.
- 36 Nishino J, Yamashita K, Hashiguchi H, Fujii H, Shimazaki T, Hamada H. Meteorin: a secreted protein that regulates glial cell differentiation and promotes axonal extension. *EMBO J* 2004; 23: 1998–2008.
- 37 Jorgensen JR, Thompson L, Fjord-Larsen L, Krabbe C, Torp M, Kalkkinen N, et al. Characterization of Meteorin – an evolutionary conserved neurotrophic factor. *J Mol Neurosci* 2009; 39: 104–16.
- 38 Mitra N, Sinha S, Ramya TN, Surolia A. N-linked oligosaccharides as outfitters for glycoprotein folding, form and function. *Trends Biochem Sci* 2006; 31: 156–63.
- 39 Kim YY, Moon JS, Kwon MC, Shin J, Im SK, Kim HA, et al. Meteorin regulates mesendoderm development by enhancing nodal expression. *PLoS One* 2014; 9: e88811.
- 40 Jorgensen JR, Emerich DF, Thanos C, Thompson LH, Torp M, Bintz B, et al. Lentiviral delivery of meteorin protects striatal neurons against excitotoxicity and reverses motor deficits in the quinolinic acid rat model. *Neurobiol Dis* 2011; 41: 160–8.
- 41 Ushach I, Burkhardt AM, Martinez C, Hevezi PA, Gerber PA, Buhren BA, et al. METEORIN-LIKE is a cytokine associated with barrier tissues and alternatively activated macrophages. *Clin Immunol* 2015; 156: 119–27.
- 42 Tanaka A, Lai-Cheong JE, van den Akker PC, Nagy N, Millington G, Diercks GF, et al. The molecular skin pathology of familial primary localized cutaneous amyloidosis. *Exp Dermatol* 2010; 19: 416–23.
- 43 Lanni C, Stanga S, Racchi M, Govoni S. The expanding universe of neurotrophic factors: therapeutic potential in aging and age-associated disorders. *Curr Pharm Des* 2010; 16: 698–717.
- 44 Revilla S, Ursulet S, Alvarez-Lopez MJ, Castro-Freire M, Perpina U, Garcia-Mesa Y, et al. Lenti-GDNF gene therapy protects against Alzheimer's disease-like neuropathology in 3xTg-AD mice and MC65 cells. *CNS Neurosci Ther* 2014; 20: 961–72.
- 45 Wong WK, Cheung AW, Yu SW, Sha O, Cho EY. Hepatocyte growth factor promotes long-term survival and axonal regeneration of retinal ganglion cells after optic nerve injury: comparison with CNTF and BDNF. *CNS Neurosci Ther* 2014; 20: 916–29.
- 46 Li ST, Pan J, Hua XM, Liu H, Shen S, Liu JF, et al. Endothelial nitric oxide synthase protects neurons against ischemic injury through regulation of brain-derived neurotrophic factor expression. *CNS Neurosci Ther* 2014; 20: 154–64.
- 47 Chen XM, Wang NN, Zhang TY, Wang F, Wu CF, Yang JY. Neuroprotection by sildenafil: neuronal networks potentiation in acute experimental stroke. *CNS Neurosci Ther* 2014; 20: 40–9.
- 48 Watanabe K, Akimoto Y, Yugi K, Uda S, Chung J, Nakamuta S, et al. Latent process genes for cell differentiation are common decoders of neurite extension length. *J Cell Sci* 2012; 125: 2198–211.
- 49 Zeve D, Tang W, Graff J. Fighting fat with fat: the expanding field of adipose stem cells. *Cell Stem Cell* 2009; 5: 472–81.
- 50 Cristancho AG, Lazar MA. Forming functional fat: a growing understanding of adipocyte differentiation. *Nat Rev Mol Cell Biol* 2011; 12: 722–34.
- 51 Cao L, Choi EY, Liu X, Martin A, Wang C, Xu X, et al. White to brown fat phenotypic switch induced by genetic and environmental activation of a hypothalamic-adipocyte axis. *Cell Metab* 2011; 14: 324–38.
- 52 Cinti S. The role of brown adipose tissue in human obesity. *Nutr Metab Cardiovasc Dis* 2006; 16: 569–74.
- 53 Fenzl A, Kiefer FW. Brown adipose tissue and thermogenesis. *Horm Mol Biol Clin Invest* 2014; 19: 25–37.
- 54 Porter C, Chondronikola M, Sidossis LS. The therapeutic potential of brown adipocytes in humans. *Front Endocrinol (Lausanne)* 2015; 6: 156.
- 55 Rao RR, Long JZ, White JP, Svensson KJ, Lou J, Lokurkar I, et al. Meteorin-like is a hormone that regulates immune-adipose interactions to increase beige fat thermogenesis. *Cell* 2014; 157: 1279–91.
- 56 Bai Z, Wuren T, Liu S, Han S, Chen L, McClain D, et al. Intermittent cold exposure results in visceral adipose tissue “browning” in the plateau pika (*Ochotona curzoniae*). *Comp Biochem Physiol A Mol Integr Physiol* 2015; 184: 171–8.
- 57 Bartelt A, Heeren J. Adipose tissue browning and metabolic health. *Nat Rev Endocrinol* 2014; 10: 24–36.
- 58 Lee SD, Tontonoz P. Eosinophils in fat: pink is the new brown. *Cell* 2014; 157: 1249–50.
- 59 Ohashi K, Shibata R, Murohara T, Ouchi N. Role of anti-inflammatory adipokines in obesity-related diseases. *Trends Endocrinol Metab* 2014; 25: 348–55.
- 60 Xu TY, Lan XH, Guan YF, Zhang SL, Wang X, Miao CY. Chronic nicotine treatment enhances vascular smooth muscle relaxation in rats. *Acta Pharmacol Sin* 2015; 36: 429–39.
- 61 Bluher M. Adipokines-removing road blocks to obesity and diabetes therapy. *Mol Metab* 2014; 3: 230–40.
- 62 Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. *Nat Rev Immunol* 2011; 11: 85–97.
- 63 Ma X, Lee P, Chisholm DJ, James DE. Control of adipocyte differentiation in different fat depots; implications for pathophysiology or therapy. *Front Endocrinol (Lausanne)* 2015; 6: 1.
- 64 Semple RK, Chatterjee VK, O'Rahilly S. PPAR gamma and human metabolic disease. *J Clin Invest* 2006; 116: 581–9.
- 65 Siersbaek R, Nielsen R, Mandrup S. PPARgamma in adipocyte

- differentiation and metabolism--novel insights from genome-wide studies. *FEBS Lett* 2010; 584: 3242–9.
- 66 Gustafson B, Smith U. Regulation of white adipogenesis and its relation to ectopic fat accumulation and cardiovascular risk. *Atherosclerosis* 2015; 241: 27–35.
- 67 McLaughlin T, Sherman A, Tsao P, Gonzalez O, Yee G, Lamendola C, *et al*. Enhanced proportion of small adipose cells in insulin-resistant vs insulin-sensitive obese individuals implicates impaired adipogenesis. *Diabetologia* 2007; 50: 1707–15.
- 68 McLaughlin T, Deng A, Yee G, Lamendola C, Reaven G, Tsao PS, *et al*. Inflammation in subcutaneous adipose tissue: relationship to adipose cell size. *Diabetologia* 2010; 53: 369–77.
- 69 McLaughlin T, Lamendola C, Coghlan N, Liu TC, Lerner K, Sherman A, *et al*. Subcutaneous adipose cell size and distribution: relationship to insulin resistance and body fat. *Obesity (Silver Spring)* 2014; 22: 673–80.
- 70 Gong WY, Liu Y, Zheng RM, Oiu GX, Lin SO. Metrnl: A new secreted protein inhibit differentiation of MG-63. *J Bone Miner Res* 2007; 22: S142.



This work is licensed under the Creative Commons Attribution-NonCommercial-No Derivative Works 3.0 Unported License. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-nd/3.0/>